MoonLake Immunotherapeutics Dossier
Qualitative Analysis
Business overview
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotechnology company headquartered in Zug, Switzerland, focused on developing next-level therapies for inflammatory skin and joint diseases. The company's single-asset pipeline centers on sonelokimab (SLK), a novel, tri-specific, albumin-binding Nanobody designed to selectively inhibit IL-17A and IL-17F. This mechanism targets the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive chronic inflammation. MoonLake is advancing SLK across multiple high-value indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and palmoplantar pustulosis (PPP).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of sonelokimab, a tri-specific Nanobody targeting IL-17A and IL-17F, across multiple inflammatory skin and joint diseases including Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (axSpA), and Palmoplantar Pustulosis (PPP).
Expected impact: Establishes sonelokimab as a highly competitive, potentially best-in-class therapeutic option across a combined addressable market exceeding $40 billion by 2035.
Building out internal commercial capabilities, including marketing, market access, and pricing functions, to prepare for the anticipated U.S. commercial launch of sonelokimab.
Expected impact: Enables independent commercialization and rapid market uptake of sonelokimab in the United States upon regulatory approval.
Securing and managing non-dilutive capital to fund late-stage clinical trials and commercial preparations while minimizing equity dilution.
Expected impact: Provides financial flexibility and extends the company's cash runway through the end of 2027, de-risking operational execution.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides a non-dilutive credit facility of up to $500 million, structured in milestone-based tranches, to support pipeline development and commercial preparations.
Terms: Up to $500 million total facility; $75 million drawn at closing in March 2025, $25 million drawn upon amendment in February 2026, with remaining tranches tied to clinical and regulatory milestones (e.g., VELA Week 52 data, BLA submission, and FDA approval).
Secures third-party contract manufacturing organization (CMO) capabilities for drug substance production, drug product manufacturing, and autoinjector development.
Terms: Terms are confidential under commercial supply and development agreements.